Does Aprepitant Interact with Ifosfamide?
CDI records a major classification for Aprepitant and Ifosfamide. The stored summary is: Increased chemotherapeutic agent exposure may increase risk of adverse reactions. Monitor for chemotherapy-related adverse effects. The mechanism involves cyp3a4 inhibition. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Aprepitant Class
- Substance P/Neurokinin-1 Receptor Antagonist
- Ifosfamide Class
- Alkylating Drug
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP3A4 inhibition
What To Tell Your Doctor or Pharmacist
If you are taking Aprepitant and your doctor is considering prescribing Ifosfamide (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider